t
On 23 January 2026, IXICO plc announced that all resolutions put forward at its Annual General Meeting held earlier that day were duly passed. These resolutions included the re-election of five directors, the re-appointment of Moore Kingston Smith as auditors, and the approval of an allotment of securities and the disapplication of pre-emption provisions. A total of 63.10% of the company's 92,668,598 ordinary shares with voting rights participated in the vote, with all resolutions receiving between 99.79% and 100.00% of votes in favour.
| Date | 23 Jan 2026 |
| Time | 17:05:49 |
| Category | AGMs and other meetings |
| ID | 2335Q |
23 January 2026
IXICO plc
("IXICO" or the "Company")
Results of AGM
IXICO plc (AIM: IXI), a global leader in neuroscience precision medicine and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, announces that all resolutions put forward to its Annual General Meeting held earlier today were duly passed and the votes cast were as follows:
|
|
RESOLUTION |
VOTES |
% |
VOTES |
% |
VOTES |
% ISC VOTED |
VOTES |
|
1 |
Reports and Accounts |
58,472,204 |
99.99% |
6,000 |
0.01% |
58,478,204 |
63.10 |
1,700 |
|
2a |
Re-election of Bram Goorden |
58,465,677 |
99.99% |
6,600 |
0.01% |
58,472,277 |
63.10 |
7,627 |
|
2b |
Re-election of Grant Nash |
58,465,677 |
99.99% |
6,600 |
0.01% |
58,472,277 |
63.10 |
7,627 |
|
2c |
Re-election of Mark Warne |
58,465,677 |
99.99% |
6,600 |
0.01% |
58,472,277 |
63.10 |
7,627 |
|
2d |
Re-election of Dr Dipti Amin |
58,465,677 |
99.99% |
6,600 |
0.01% |
58,472,277 |
63.10 |
7,627 |
|
2e |
Re-election of Kate Rogers |
58,465,677 |
99.99% |
6,600 |
0.01% |
58,472,277 |
63.10 |
7,627 |
|
3 |
Re-appointment of Moore Kingston Smith Auditors |
58,475,004 |
100.00% |
2,800 |
0.00% |
58,477,804 |
63.10 |
2,100 |
|
4 |
Allotment of Securities |
58,475,336 |
100.00% |
1,800 |
0.00% |
58,477,136 |
63.10 |
2,768 |
|
5 |
* Disapply Pre-Emption Provisions |
58,354,629 |
99.79% |
122,507 |
0.21% |
58,477,136 |
63.10 |
2,768 |
* Special Resolution
For the purposes of section 341 of the Companies Act 2006, IXICO plc's total issued share capital with voting rights as at 6.30pm on 22 January 2026, being the time at which a shareholder had to be registered in the Company's register of members in order to attend and vote at the AGM, was 92,668,598 ordinary shares.
Please note that a 'vote withheld' is not a vote under English Law and is not counted in the calculation
of the proportion of the votes 'for' and 'against' a resolution.
For further information please contact:
|
IXICO plc |
+44 (0) 20 3763 7499 |
|
Grant Nash, Chief Financial Officer James Chandler, Chief Business Officer |
|
|
Cavendish Capital Markets Limited (Nominated Adviser and Sole Broker) |
+44 (0) 20 7220 0500 |
|
Giles Balleny (Corporate Finance) Nigel Birks (Healthcare Specialist Sales) Harriet Ward (Corporate Broking) Michael F Johnson (Sales) |
|
About IXICO www.IXICO.com
IXICO is a global leader in neuroscience imaging and biomarker analytics, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring. As a key part of the global neurological disease research community, the Company has built a global reputation and 20-year track record as an end-to-end Imaging Contract Research Organisation (iCRO) working with leading pharma companies, innovative biotech's, disease consortia and non-profit organisations. IXICO has supported hundreds of neurological clinical trials, analysed hundreds of thousands scans and built an expansive network of expert imaging centres around the world.
The IXICO Platform is tailor-made for neurological disease, reliably processing data from global trials, precisely measuring key imaging biomarkers associated with the identification, progression and treatment of diseases such as Alzheimer's, Huntington's and Parkinson's. Image data is interrogated by the Platform and IXICO's expert scientists translating complex data into clinically meaningful while minimizing data variability and increasing reproducibility.